Monoamine Oxidase (MAO) as a Potential Target for Anticancer Drug Design and Development

Molecules. 2021 Oct 4;26(19):6019. doi: 10.3390/molecules26196019.

Abstract

Monoamine oxidases (MAOs) are oxidative enzymes that catalyze the conversion of biogenic amines into their corresponding aldehydes and ketones through oxidative deamination. Owing to the crucial role of MAOs in maintaining functional levels of neurotransmitters, the implications of its distorted activity have been associated with numerous neurological diseases. Recently, an unanticipated role of MAOs in tumor progression and metastasis has been reported. The chemical inhibition of MAOs might be a valuable therapeutic approach for cancer treatment. In this review, we reported computational approaches exploited in the design and development of selective MAO inhibitors accompanied by their biological activities. Additionally, we generated a pharmacophore model for MAO-A active inhibitors to identify the structural motifs to invoke an activity.

Keywords: QSAR; cancer; inhibitors; metastasis; monoamine oxidase; pharmacophore.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use
  • Computational Biology
  • Drug Design
  • Drug Development
  • Humans
  • Monoamine Oxidase
  • Monoamine Oxidase Inhibitors / pharmacology
  • Monoamine Oxidase Inhibitors / therapeutic use*
  • Neoplasms / drug therapy
  • Neoplasms / enzymology*
  • Quantitative Structure-Activity Relationship

Substances

  • Antineoplastic Agents
  • Monoamine Oxidase Inhibitors
  • Monoamine Oxidase